Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract - 1 Aug 2018

Jung Jinmin, Kwon Jae Hyun, Song Gi-Won, Tak Eun-Young, Kirchner Vavara A, Lee Sung-Gyu

Abstract excerpt

BACKGROUND: Hepatitis C virus (HCV) universally recurs after liver transplantation (LT). Although the introduction of direct-acting antiviral agents (DAAs) has revolutionized the treatment of HCV infection, no optimal treatment for HCV recurrence after LT has been developed. METHODS: This study retrospectively evaluated the efficacy of DAAs as a pre-emptive treatment for recurrent HCV infection after living donor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fluorenes
Share to Isoquinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Living Donors

Share to Pyrrolidines

Share to Secondary Prevention

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Uridine Monophosphate

Source

Identifiers

PMID: 29679347
DOI: 10.1007/s11605-018-3779-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.PMID 29679347Read ↗

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.Semantic proximity Read ↗

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Semantic proximity Read ↗

Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.Semantic proximity Read ↗

Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.Semantic proximity Read ↗

Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.Semantic proximity Read ↗

Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.Semantic proximity Read ↗

Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.Semantic proximity Read ↗

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.Semantic proximity Read ↗

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.